After Roche/Genentech: Pharma's Focus on Efficiencies, Not Innovation

Roche's rationale for buying Genentech must out-argue the one big reason not to do the deal: theirs has been the most successful relationship in pharmaceutical history. Instead, Roche is betting that this unique relationship has already borne its best fruit. In an emerging world of payor constraints, biological me-toos and growing oncology marketing expenses, the costs of keeping Genentech independent -- manufacturing transfer prices, up-front fees and royalties, and most importantly, no ability to leverage its investment in the US marketplace -- are simply too high. Moreover, Roche is clearly not convinced that Genentech's productivity would have continued at the rates it has in the last decade. Roche's vision of the pharma future looks a lot more like the cost-constrained world CEO Schwan knew at Roche Diagnostics - where innovation was rare and rarely paid for; where extraordinary business acumen counted for more than outsized research capabilities.

As IN VIVO was going to press, Roche announced it was offering $43.7 billion for the 44% of Genentech Inc. it didn’t already own. [See Deal]

The question is why? Certainly, Roche’s earnings are slowing and buying the remainder of Genentech will allow it to consolidate...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from Business Strategy

More from In Vivo